Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AOC2 | O75106 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112803 | 0.82 | MEN1 (0.53) | — | |
| SCHEMBL6574222 | 0.79 | MAOB (0.53) | MAOBALDH1A1 | |
| SCHEMBL31391958 | 0.78 | HRH3 (0.41) | SYKMAOBAPPL3MBTL1GAA | |
| SCHEMBL9785630 | 0.78 | GAA (0.62) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL2781336 | 0.77 | SOD1 (0.39) | SYKL3MBTL1GAAALDH1A1 | |
| SCHEMBL2061077 | 0.77 | TDP1 (0.52) | SYKMAOBAPPL3MBTL1TDP1 | |
| SCHEMBL3357599 | 0.77 | ALDH1A1 (0.46) | SYKL3MBTL1GAAALDH1A1 | |
| SCHEMBL187687 | 0.77 | ALDH3A1 (0.50) | SYKMAOBAPPL3MBTL1CYP1A2 | |
| SCHEMBL3830326 | 0.77 | CA12 (0.53) | MAOBAPPMAOA | |
| SCHEMBL19012000 | 0.77 | SYK (0.40) | SYKMAOBL3MBTL1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3974426-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research and Technology Corporation (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3349581-B1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-108347942-B | Hepatitis B core protein modulators | 组装生物科学股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| CN-106413402-B | Hepatitis b core protein allosteric modulators | 美国印第安纳大学研究和技术公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10766890-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766890-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-6215001-B1 | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS, AND ANTIALLERGENS; SIDE EFFECT REDUCTION | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-04-10 | — | — | US | disclosed |
| WO-2000078737-A2 | ARYLOXY ETHYLAMINO TRIAZINES AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | disclosed |
| US-6031109-A | Phenoxy-, phenylthio-, benzoyl-alkyleneaminoalkylene-imidazole derivatives as therapeutic agents | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| CN-1043228-C | Process for producing halogenophennoxyfatty acid derivatives by selective halogenation and halogenophenoxyfatty acid derivatives | NIHON NOHYAKU CO LTD (JP) | 1999-05-05 | — | — | CN | disclosed |
| US-5780642-A | NON-STEROIDAL ANTIINFLAMMATORY AGENT WHICH BLOCKS RELEASE OF ARACHIDONIC ACID FROM PHOSPHOLIPIDS; SIDE EFFECT REDUCTION | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-14 | — | — | US | disclosed |
| EP-0705251-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000493-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
| CN-1078232-A | Selective halogenation prepares the method and the halogenated phenoxy fatty acid derivative of halogenated phenoxy fatty acid derivative | NIHON NOHYAKU CO LTD (JP) | 1993-11-10 | — | — | CN | disclosed |
| US-4370278-A | Nucleophilic substitution process | ETHYL CORPORATION (US) | 1983-01-25 | — | — | US | disclosed |
| US-4006185-A | CHEMICAL INTERMEDIATES | OLIN CORPORATION (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | SYK 3267/4885MAOB 3802/4885APP 3207/4885 |
| US-10766890-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | SYK 3733/4885MAOB 3692/4885APP 3264/4885 |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | HAVCR2, MAVS, FABP1 | SYK 3267/4885MAOB 3802/4885APP 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.